On Apr. 8, 2020, Abbott announced that the FreeStyle Libre 14 day system, a continuous glucose monitoring (CGM) technology, can now be used in the hospital setting during the COVID-19 pandemic, according to the FDA. This permited frontline healthcare workers to remotely monitor patients with diabetes receiving inpatient care by assessing real-time glucose levels4 and glucose history.

To help hospitals and medical centers in COVID-19 outbreak hotspots ramp up access to the technology, Abbott will donated 25,000 FreeStyle Libre 14 day sensors in partnership with the American Diabetes Association (ADA), Insulin for Life USA and Diabetes Disaster Response Coalition.